Sana Biotechnology Inc Total Liabilities
Sana Biotechnology Inc total liabilities. Based on the latest financial reports, Sana Biotechnology Inc (SANA) has total liabilities worth $276.95 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Sana Biotechnology Inc (SANA) liquidity interval to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Sana Biotechnology Inc (2018–2025)
Total liabilities of Sana Biotechnology Inc from 2018 to 2025. This chart illustrates how Sana Biotechnology Inc's total liabilities have evolved over time, based on quarterly financial data. Check SANA asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Sana Biotechnology Inc Competitors by Total Liabilities
The table below lists competitors of Sana Biotechnology Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shijiazhuang Kelin Elec Co
SHG:603050
|
China | CN¥3.11 Billion |
|
Hang Xiao Steel Structure Co Ltd
SHG:600477
|
China | CN¥10.09 Billion |
|
Shandong Mining Machinery Group Co Ltd
SHE:002526
|
China | CN¥2.05 Billion |
|
Latham Group Inc
NASDAQ:SWIM
|
USA | $448.94 Million |
|
Greenworks (Jiangsu) Co. Ltd. A
SHE:301260
|
China | CN¥6.07 Billion |
|
Shenzhen JT Automation Equipment Co Ltd
SHE:300400
|
China | CN¥434.37 Million |
|
Jiangxi Hungpai New Material Co Ltd
SHG:605366
|
China | CN¥1.28 Billion |
|
Kelsian Group Ltd
AU:KLS
|
Australia | AU$1.56 Billion |
Liability Composition Analysis (2018–2025)
This chart breaks down Sana Biotechnology Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Sana Biotechnology Inc assets under control.
Liquidity & Leverage Metrics
Sana Biotechnology Inc Total Liabilities Ratios Explained
Sana Biotechnology Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.38 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.79 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.64 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sana Biotechnology Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sana Biotechnology Inc (2018–2025)
The table below shows the annual total liabilities of Sana Biotechnology Inc from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $256.01 Million | +2.19% |
| 2024-12-31 | $250.52 Million | -9.82% |
| 2023-12-31 | $277.79 Million | -14.10% |
| 2022-12-31 | $323.40 Million | -19.33% |
| 2021-12-31 | $400.90 Million | -65.18% |
| 2020-12-31 | $1.15 Billion | +106.46% |
| 2019-12-31 | $557.73 Million | +1073.66% |
| 2018-12-31 | $47.52 Million | -- |
About Sana Biotechnology Inc
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline includes UP421, a HIP-modified allogeneic primary… Read more